白蛋白结合型紫杉醇对比多西他赛治疗经治晚期非小细胞肺癌的3期试验
这项随机、开放标签、非劣效3期试验纳入503例既往接受过细胞毒性化疗的晚期NSCLC患者,1:1分配接受多西他赛(60 mg/m2,第1天)或白蛋白结合型紫杉醇(100 mg/m2,第1、8、15天,21天周期)。主要终点OS在ITT人群分析:nab-紫杉醇组中位OS 16.2个月(95%CI 14.4-19.0),多西他赛组13.6个月(95%CI 10.9-16.5),HR=0.85(95.2%CI 0.68-1.07),达到非劣效。
要点
- nab-紫杉醇组中位OS 16.2个月,多西他赛组13.6个月,HR=0.85(95.2%CI 0.68-1.07),非劣效。
- nab-紫杉醇组中位PFS 4.2个月 vs 3.4个月(HR=0.76,95%CI 0.63-0.92,p=0.0042)。
- nab-紫杉醇组ORR 29.9% vs 15.4%(p=0.0002);≥3级发热性中性粒细胞减少2% vs 22%。
核心结论
- 白蛋白结合型紫杉醇在OS方面非劣效于多西他赛,应被视为经治晚期NSCLC的标准治疗选择之一。
研究设计与样本
- 随机、开放标签、非劣效3期试验,纳入503例既往接受过细胞毒性化疗的晚期NSCLC患者,1:1随机分配。
- 多西他赛组(251例)接受60 mg/m2第1天给药,nab-紫杉醇组(252例)接受100 mg/m2第1、8、15天给药,21天为一周期。
主要发现
- nab-紫杉醇组中位OS为16.2个月(95%CI 14.4-19.0),多西他赛组为13.6个月(95%CI 10.9-16.5),HR=0.85(95.2%CI 0.68-1.07)。
- nab-紫杉醇组中位PFS为4.2个月(95%CI 3.9-5.0),多西他赛组为3.4个月(95%CI 2.9-4.1),HR=0.76(95%CI 0.63-0.92,p=0.0042)。
- nab-紫杉醇组ORR为29.9%(95%CI 24.0-36.2),多西他赛组为15.4%(95%CI 10.9-20.7),p=0.0002。
- ≥3级不良事件:发热性中性粒细胞减少在nab-紫杉醇组为5/245例(2%),多西他赛组为55/249例(22%);周围感觉神经病变分别为24例(10%)和2例(1%)。
临床怎么用
- 对于既往接受过细胞毒性化疗的晚期NSCLC患者,可考虑使用白蛋白结合型紫杉醇作为多西他赛的替代标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to evaluate the efficacy and safety of nanoparticle albumin-bound (nab-) paclitaxel for previously treated patients with advanced NSCLC. METHODS: In this randomized, open-label, noninferiority phase 3 trial, we enrolled patients with advanced NSCLC previously treated with cytotoxic chemotherapy. Patients were randomly allocated (1:1) to receive docetaxel (60 mg/m2) on day 1 or nab-paclitaxel (100 mg/m2) on days 1, 8, and 15 of a 21-day cycle. The primary end point was overall survival (OS) analyzed on an intention-to-treat basis. RESULTS: Between May 22, 2015, and March 12, 2018, a total of 503 patients were randomly allocated to the treatment. Median OS was 16.2 months (95% confidence interval [CI]: 14.4-19.0) for the 252 patients allocated to nab-paclitaxel and 13.6 months (95% CI: 10.9-16.5) for the 251 patients allocated to docetaxel (hazard ratio = 0.85, 95.2% CI: 0.68-1.07). Median progression-free survival was 4.2 months (95% CI: 3.9-5.0) for the nab-paclitaxel group versus 3.4 months (95% CI: 2.9-4.1) for the docetaxel group (hazard ratio = 0.76, 95% CI: 0.63-0.92, p = 0.0042). The objective response rate was 29.9% (95% CI: 24.0-36.2) for the nab-paclitaxel group and 15.4% (95% CI: 10.9-20.7) for the docetaxel group (p = 0.0002). Adverse events of grade greater than or equal to 3 included febrile neutropenia (5 of 245 patients [2%] in the nab-paclitaxel group versus 55 of 249 patients [22%] in the docetaxel group) and peripheral sensory neuropathy (24 [10%] versus 2 [1%], respectively). CONCLUSIONS: Nab-paclitaxel was noninferior to docetaxel in terms of OS. It should, thus, be considered a standard treatment option for previously treated patients with advanced NSCLC.
引用
- Yoneshima Y, Morita S, Ando M, et al. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. J Thorac Oncol. 2021. PMID: 33915251. doi:10.1016/j.jtho.2021.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。